IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation

被引：0

作者：

Kaseb, Ahmed ^{[1
]}

Chen, Minshan ^{[2
]}

Chow, Pierce ^{[3
,4
]}

Kudo, Masatoshi ^{[5
]}

Lee, Han Chu ^{[6
]}

Yopp, Adam ^{[7
]}

Becker, Lars ^{[8
]}

Hernandez, Sairy ^{[9
]}

Kovic, Bruno ^{[10
]}

Lian, Qinshu ^{[9
]}

Ma, Ning ^{[9
]}

Wu, Chun ^{[11
]}

Qin, Shukui ^{[12
]}

Cheng, Ann-Lii ^{[13
,14
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China

[3] Natl Canc Ctr Singapore, Singapore, Singapore

[4] Duke NUS Med Sch Singapore, Singapore, Singapore

[5] Kindai Univ, Osaka, Japan

[6] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[7] UT SouthWestern Med Ctr, Dallas, TX USA

[8] F Hoffmann La Roche, Basel, Switzerland

[9] Genentech Inc, San Francisco, CA USA

[10] Hoffmann La Roche Ltd, Mississauga, ON, Canada

[11] Roche China Holding Ltd, Shanghai, Peoples R China

[12] Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China

[13] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[14] Natl Taiwan Univ Hosp, Taipei, Taiwan

来源：

JOURNAL OF HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

GS-011

引用

页码：S9 / S10

页数：2

共 19 条

[1] Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Kudo, Masatoshi
Chen, Minshan
Chow, Pierce K. H.
Kaseb, Ahmed Omar
Lee, Han Chu
Yopp, Adam C.
Becker, Lars
Painter, Sairy Hernandez
Kovic, Bruno
Lian, Qinshu
Ma, Ning
Wu, Chun
Qin, Shukui
Cheng, Ann-Lii
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Imbrave050: Phase 3 Study of Adjuvant Atezolizumab plus Bevacizumab vs Active Surveillance in Patients with Hepatocellular Carcinoma at High Risk of Disease Recurrence after Resection or Ablation
Yopp, Adam Charles
Cheng, Ann-Lii
Kaseb, Ahmed Omar
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S19 - S19
[3] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Trojan, J.
Chow, P.
Chen, M.
Cheng, A-L
Kaseb, A.
Kudo, M.
Lee, H. C.
Yopp, A.
Zhou, J.
Wang, L.
Wen, X.
Heo, J.
Tak, W-Y
Nakamura, S.
Numata, K.
Uguen, T.
Hsieh, D.
Cha, E.
Hack, S. P.
Lian, Q.
Spahn, J.
Wu, C.
Qin, S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 239 - 239
[4] Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
Yopp, A.
Kudo, M.
Chen, M.
Cheng, A-L.
Kaseb, A. O.
Lee, H. C.
Qin, S.
Cha, E.
Hack, S. P.
Lian, Q.
Spahn, J.
Wu, C.
Chow, P.
ANNALS OF ONCOLOGY, 2024, 35 : 1230 - 1230
[5] Efficacy of atezolizumab (atezo) plus bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)
He, A. R. R.
Numata, K.
Lee, K-H.
Hsu, C-H.
Lee, J.
Morimoto, M.
Verret, W.
Hack, S. P.
Spahn, J.
Liu, B.
Ryoo, B-Y.
ANNALS OF ONCOLOGY, 2020, 31 : S690 - S690
[6] Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
Galle, Peter R.
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Zhu, Andrew X.
Kim, Tae-You
Kudo, Masatoshi
Breder, Valeriy Vladimirovich
Merle, Philippe
Kaseb, Ahmed Omar
Li, Daneng
Mulla, Sohail
Verret, Wendy
Xu, Derek-Zhen
Hernandez, Sairy
Liu, Juan
Huang, Chen
Lim, Ho Yeong
Cheng, Ann-Lii
Ducreux, Michel
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[7] IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
Hack, Stephen P.
Spahn, Jessica
Chen, Minshan
Cheng, Ann-Lii
Kaseb, Ahmed
Kudo, Masatoshi
Lee, Han Chu
Yopp, Adam
Chow, Pierce
Qin, Shukui
FUTURE ONCOLOGY, 2020, 16 (15) : 975 - 989
[8] IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Mertens, Joachim
Kim, Tae-You
Kudo, Masatoshi
Lim, Ho Yeong
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Feng, Yin-Hsun
Verret, Wendy
Nicholas, Alan
Li, Lindong
Ma, Ning
Zhu, Andrew X.
Cheng, Ann-Lii
SWISS MEDICAL WEEKLY, 2021, 151 : 25 - 26
[9] IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Lim, Ho Yeong
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Feng, Yin-Hsun
Verret, Wendy
Nicholas, Alan
Li, Lindong
Ma, Ning
Zhu, Andrew X.
Cheng, Ann-Lii
CANCER RESEARCH, 2021, 81 (13)
[10] IMbrave150: EXPLORATORY EFFICACY AND SAFETY OF ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL PHASE III STUDY
Zhu, Andrew X.
Finn, Richard
Ducreux, Michel
Hu, Youyou
Sommer, Nicolas
Verret, Wendy
Kulik, Laura M.
Galle, Peter R.
HEPATOLOGY, 2021, 74 : 646A - 647A

← 1 2 →